Physician profile
Daniel Rau
NPI 1518684216
$1,431.97
in general payments reported to CMS, 2019-2025
23 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $155 · 2023: $836 · 2024: $226 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $225.67 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $187.69 | 2023-2025 | |
| Indivior INC. | $133.49 | 2024-2025 | Sublocade |
| Janssen Scientific Affairs, LLC | $114.48 | 2022 | |
| Amgen INC. | $103.22 | 2023 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $99.63 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $68.85 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.57 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $66.21 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $60.63 | 2023-2024 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $46.93 | 2023-2024 | Auvelity |
| Antares Pharma, INC. | $39.23 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Noven Therapeutics, LLC | $26.18 | 2023 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2023 | Trintellix |
| Halozyme INC | $24.44 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.53 | 2024 | Jardiance |
| Seqirus USA INC | $19.27 | 2022 | |
| Organon LLC | $18.84 | 2024 | |
| Kyowa Kirin, INC. | $17.86 | 2025 | |
| Novo Nordisk INC | $17.44 | 2023 | Wegovy |
| Insulet Corporation | $15.70 | 2023 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $15.64 | 2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.